Pfizer Submits Olectiv, Lectiv As Names For Incontinence Agent
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Olectiv and Lectiv are the latest names Pfizer has submitted to the Patent and Trademark Office for an incontinence therapy. The names could be under consideration for the firm’s incontinence agent darifenacin, which is in Phase III trials.